Cargando…

Long-Term Storage Effects on Stability of Aβ(1–40), Aβ(1–42), and Total Tau Proteins in Human Plasma Samples Measured with Immunomagnetic Reduction Assays

BACKGROUND: The stability of Alzheimer's disease (AD) biomarkers in plasma, measured by immunomagnetic reduction (IMR) after long-term storage at −80°C, has not been established before. METHOD: Ninety-nine human plasma samples from 53 normal controls (NCs), 5 patients with amnestic mild cogniti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiu, Ming-Jang, Lue, Lih-Fen, Sabbagh, Marwan N., Chen, Ta-Fu, Chen, H.H., Yang, Shieh-Yueh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477481/ https://www.ncbi.nlm.nih.gov/pubmed/31043966 http://dx.doi.org/10.1159/000496099

Ejemplares similares

Age-Dependent Relationship Between Plasma Aβ40 and Aβ42 and Total Tau Levels in Cognitively Normal Subjects
por: Lue, Lih-Fen, et al.
Publicado: (2019)

Corrigendum: Age-Dependent Relationship Between Plasma Aβ40 and Aβ42 and Total Tau Levels in Cognitively Normal Subjects
por: Lue, Lih-Fen, et al.
Publicado: (2019)

Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts
por: Lue, Lih-Fen, et al.
Publicado: (2017)

Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology
por: Lue, Lih-Fen, et al.
Publicado: (2019)

Stability of Plasma Amyloid-β 1–40, Amyloid-β 1–42, and Total Tau Protein over Repeated Freeze/Thaw Cycles
por: Liu, Huei-Chun, et al.
Publicado: (2020)

Immunomagnetic Reduction Detects Plasma Aβ(1–42) Levels as a Potential Dominant Indicator Predicting Cognitive Decline
por: Yang, Shieh-Yueh, et al.
Publicado: (2020)

Tau pathogenesis is promoted by Aβ1-42 but not Aβ1-40
por: Hu, Xiaoyan, et al.
Publicado: (2014)

Synergistic Association between Plasma Aβ(1–42) and p-tau in Alzheimer’s Disease but Not in Parkinson’s Disease or Frontotemporal Dementia
por: Chiu, Ming-Jang, et al.
Publicado: (2021)

Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer’s Disease
por: Yang, Shieh-Yueh, et al.
Publicado: (2017)

The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone
por: Delaby, Constance, et al.
Publicado: (2022)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40(ox)% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia
por: Bibl, Mirko, et al.
Publicado: (2010)

Nonphosphorylated tau slows down Aβ(1–42) aggregation, binds to Aβ(1–42) oligomers, and reduces Aβ(1–42) toxicity
por: Beeg, Marten, et al.
Publicado: (2021)

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?
por: Klafki, Hans-Wolfgang, et al.
Publicado: (2022)

Diagnostic Utility of Selected Serum Dementia Biomarkers: Amyloid β-40, Amyloid β-42, Tau Protein, and YKL-40: A Review
por: Wilczyńska, Karolina, et al.
Publicado: (2020)

Amyloid β-peptides 1–40 and 1–42 form oligomers with mixed β-sheets
por: Baldassarre, Maurizio, et al.
Publicado: (2017)

Admission Levels of Total Tau and β-Amyloid Isoforms 1–40 and 1–42 in Predicting the Outcome of Mild Traumatic Brain Injury
por: Hossain, Iftakher, et al.
Publicado: (2020)

Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40
por: Suire, Caitlin N., et al.
Publicado: (2020)

Dynamic Blood Concentrations of Aβ(1–40) and Aβ(1–42) in Alzheimer’s Disease
por: Yang, Yuan-Han, et al.
Publicado: (2020)

Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light
por: Schindler, Suzanne E., et al.
Publicado: (2022)

Development of an assay of plasma neurofilament light chain utilizing immunomagnetic reduction technology
por: Liu, Huei-Chun, et al.
Publicado: (2020)

Neurodegenerative disease biomarkers Aβ(1–40), Aβ(1–42), tau, and p‐tau(181) in the vervet monkey cerebrospinal fluid: Relation to normal aging, genetic influences, and cerebral amyloid angiopathy
por: Chen, Jason A., et al.
Publicado: (2018)

Is There Inflammatory Synergy in Type II Diabetes Mellitus and Alzheimer's Disease?
por: Lue, Lih-Fen, et al.
Publicado: (2012)

Plasma p‐tau181/Aβ(1‐42) ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ(1‐42) and future cognitive decline
por: Fowler, Christopher J., et al.
Publicado: (2022)

Effect of long-term storage in biobanks on cerebrospinal fluid biomarker Aβ(1-42), T-tau, and P-tau values
por: Willemse, Eline A.J., et al.
Publicado: (2017)

Aggregation States of Aβ(1–40), Aβ(1–42) and Aβp(3–42) Amyloid Beta Peptides: A SANS Study
por: Festa, Giulia, et al.
Publicado: (2019)

CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal Dementias
por: Constantinides, Vasilios C., et al.
Publicado: (2023)

Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s Disease
por: Chen, Nai-Ching, et al.
Publicado: (2020)

Enhanced Aβ(1–40) Production in Endothelial Cells Stimulated with Fibrillar Aβ(1–42)
por: Rajadas, Jayakumar, et al.
Publicado: (2013)

Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory
por: Lewczuk, Piotr, et al.
Publicado: (2021)

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
por: Ashton, Nicholas J., et al.
Publicado: (2022)

A novel study on amyloid β peptide 40, 42 and 40/42 ratio in Saudi autistics
por: Al- Ayadhi, Laila Y, et al.
Publicado: (2012)

Investigation of the Number of Tests Required for Assaying Plasma Biomarkers Associated with Alzheimer’s Disease Using Immunomagnetic Reduction
por: Liu, Huei-Chun, et al.
Publicado: (2021)

Increasing Precision of Clinical Diagnosis of Alzheimer's Disease Using a Combined Algorithm Incorporating Clinical and Novel Biomarker Data
por: Sabbagh, Marwan N., et al.
Publicado: (2017)

Development of a 36-Channel Instrument for Assaying Biomarkers of Ultralow Concentrations Utilizing Immunomagnetic Reduction
por: Chen, Hsin-Hsien, et al.
Publicado: (2022)

Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)
por: Vanderstichele, Hugo, et al.
Publicado: (2017)

Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study
por: Motta, Caterina, et al.
Publicado: (2023)

Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis
por: Lanznaster, Débora, et al.
Publicado: (2020)

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

The Position of Aβ(22−40) and Aβ(1−42) in Anionic Lipid Membranes Containing Cholesterol
por: Barrett, Matthew A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_juu7lv8aai3qlplfqh6j4pnv53